Principal Financial Group Inc Ultragenyx Pharmaceutical Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$40.21 - $59.36 $3.06 Million - $4.52 Million	76,150 Added 740.04%	86,440 $4.8 Million
Q2 2024 Jul 29, 2024	SELL	$37.42 - $51.61 $212,807 - $293,506	-5,687 Reduced 35.59%	10,290 $422,000
Q1 2024 Apr 29, 2024	SELL	$43.02 - $53.69 $31,404 - $39,193	-730 Reduced 4.37%	15,977 $745,000
Q4 2023 Feb 07, 2024	SELL	$31.73 - $49.19 $29,159 - $45,205	-919 Reduced 5.21%	16,707 $798,000
Q3 2023 Nov 02, 2023	BUY	$34.92 - $46.66 $24,583 - $32,848	704 Added 4.16%	17,626 $628,000
Q2 2023 Aug 07, 2023	SELL	$37.35 - $52.15 $373 - $521	-10 Reduced 0.06%	16,922 $780,000
Q1 2023 May 09, 2023	SELL	$36.99 - $48.71 $49,492 - $65,173	-1,338 Reduced 7.32%	16,932 $678,000
Q4 2022 Feb 09, 2023	BUY	$33.72 - $46.33 $85,851 - $117,956	2,546 Added 16.19%	18,270 $846,000
Q3 2022 Nov 09, 2022	SELL	$39.96 - $66.14 $29,370 - $48,612	-735 Reduced 4.47%	15,724 $651,000
Q2 2022 Aug 10, 2022	BUY	$45.8 - $85.4 $103,691 - $193,345	2,264 Added 15.95%	16,459 $982,000
Q1 2022 May 09, 2022	SELL	$62.2 - $84.4 $12,937 - $17,555	-208 Reduced 1.44%	14,195 $1.03 Million
Q4 2021 Feb 09, 2022	SELL	$73.71 - $87.86 $393,021 - $468,469	-5,332 Reduced 27.02%	14,403 $1.21 Million
Q3 2021 Nov 09, 2021	SELL	$77.92 - $102.4 $193,787 - $254,668	-2,487 Reduced 11.19%	19,735 $1.78 Million
Q2 2021 Aug 10, 2021	SELL	$92.19 - $115.71 $5.31 Million - $6.66 Million	-57,596 Reduced 72.16%	22,222 $2.12 Million
Q1 2021 May 10, 2021	BUY	$106.9 - $167.73 $5.5 Million - $8.63 Million	51,458 Added 181.45%	79,818 $9.09 Million
Q4 2020 Feb 08, 2021	BUY	$84.4 - $177.39 $622,028 - $1.31 Million	7,370 Added 35.11%	28,360 $3.93 Million
Q3 2020 Nov 06, 2020	SELL	$72.98 - $90.0 $70,863 - $87,390	-971 Reduced 4.42%	20,990 $1.73 Million
Q2 2020 Aug 05, 2020	BUY	$46.91 - $78.22 $278,504 - $464,392	5,937 Added 37.05%	21,961 $1.72 Million
Q1 2020 May 12, 2020	BUY	$33.8 - $62.9 $8,314 - $15,473	246 Added 1.56%	16,024 $712,000
Q4 2019 Feb 05, 2020	SELL	$36.08 - $45.83 $54,156 - $68,790	-1,501 Reduced 8.69%	15,778 $674,000
Q3 2019 Nov 13, 2019	BUY	$42.5 - $63.11 $69,870 - $103,752	1,644 Added 10.51%	17,279 $739,000
Q2 2019 Aug 12, 2019	BUY	$54.93 - $74.36 $36,089 - $48,854	657 Added 4.39%	15,635 $993,000
Q1 2019 May 10, 2019	BUY	$39.87 - $69.36 $61,320 - $106,675	1,538 Added 11.44%	14,978 $1.04 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $124,992 - $248,442	-3,214 Reduced 19.3%	13,440 $584,000
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $169,256 - $212,483	2,357 Added 16.49%	16,654 $1.27 Million
Q2 2018 Aug 13, 2018	BUY	$48.54 - $85.31 $59,024 - $103,736	1,216 Added 9.3%	14,297 $0
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $2,704 - $3,569	-61 Reduced 0.46%	13,081 $667,000
Q4 2017 Feb 13, 2018	SELL	$43.54 - $57.32 $2.58 Million - $3.4 Million	-59,247 Reduced 81.85%	13,142 $609,000
Q3 2017 Nov 02, 2017	BUY	$49.79 - $66.32 $3.6 Million - $4.8 Million	72,389	72,389 $3.86 Million

Others Institutions Holding RARE

# of Institutions

324

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$427 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$241 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$220 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$179 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$132 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account